This protocol addresses viral encephalitis caused by human herpesvirus 6 (HHV-6). HHV-6 encephalitis requires a targeted approach, and immune status is a critical factor shaping the treatment decision.
The protocol applies to patients with human herpesvirus 6 encephalitis. Management considerations differ between immunocompromised and immunocompetent patients, reflecting differences in available evidence for this specific viral cause.
Antiviral therapy is central to management in this setting. Which agent is selected — and whether a single agent or a combination approach is warranted — depends on clinical factors detailed in the full protocol.
DOI: 10.1086/589747
Human herpesvirus 6: ganciclovir or foscarnet should be used in immunocompromised patients (B-III); use of these agents in immunocompetent patients can be considered (C-III), but there are not good data on their effectiveness.
Despite these contradictions, treatment with one of these agents, alone or in combination, in immunocompromised patients with human herpesvirus 6 encephalitis may be reasonable, because no other therapies are currently available.
View source ↗